Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Name: GIM-531 Name (English): GIM-531
Developer: Georgiamune Inc.
Status: Currently in Phase 1/2 clinical trials.
Mechanism of Action: Selective T regulatory cell (Treg) inhibitor. It is designed to inhibit the induction and function of Tregs, which are suppressor immune cells that can impede the body's anti-tumor responses. By inhibiting Tregs, GIM-531 aims to reprogram the tumor microenvironment to allow the immune system to eliminate cancer cells.
Route of Administration: Oral.
Indication: Advanced solid tumors, including metastatic cutaneous melanoma, that have progressed on or are intolerant of standard therapies, or cancers not adequately addressed by existing immunotherapies like anti-PD-1 antibodies. Specific cohorts in the clinical trial include single-agent treatment in tumors where Tregs play a significant role and combination therapy with anti-PD-1 in anti-PD-1 failure advanced melanoma.
Clinical Trials: A Phase 1/2 open-label, multi-center study (GIM531-CT01) is ongoing to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic effects, and preliminary efficacy of GIM-531 as a single agent and in combination with an anti-PD-1 antibody in patients with advanced solid tumors. The Phase 1 portion focuses on dose escalation, while the Phase 2 portion will assess anti-tumor activity in specific tumor types and in combination with anti-PD-1 therapy.
Rationale: GIM-531 represents a novel approach to cancer immunotherapy by targeting Tregs, which are often enriched in the tumor microenvironment and contribute to immune suppression. Inhibiting Tregs may enhance the effectiveness of the body's own immune system to fight cancer and potentially overcome resistance to other immunotherapies.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/05/23 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.